Collaboration to Improve Access to Transformative Biomarker Study for Alzheimer’s Disease
Las Vegas, Nev. – Sept. 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias. This is an international study, but CNS is the only Las Vegas research site participating.
CNS is led by Dr. Leo Germin, an expert neurologist, known for offering compassionate and up-to-date care. Dr. Germin and CNS are well-suited to introduce Bio-Hermes-002 in Las Vegas as the nationwide demand for more inclusive and real-world brain health research continues to rise.
“We’re enthusiastic about our collaboration with CNS, whose commitment to delivering first-in-class care aligns with our goal of expanding Alzheimer’s research opportunities in Las Vegas,” said John Dwyer, president of the Global Alzheimer’s Platform Foundation. “With Dr. Germin’s leadership at CNS, GAP will expand opportunities and help to make Alzheimer’s research more accessible to people in the entire Las Vegas-area community.”
As a part of the collaboration, GAP Clinical Research Program Manager Sarah Freeland will oversee the Bio-Hermes-002 study locally. Serving as the key on-site leader, Freeland brings a wealth of experience having led trials across multiple therapeutic areas.
“With nearly 55,000 Nevadans living with Alzheimer’s today, the need for accelerating research is clear,” said Dr. Germin. “In collaborating with the Global Alzheimer’s Platform Foundation, CNS will have a direct pathway for patients who could benefit from opportunities with clinical trials. We are excited for this new partnership and look forward to helping improve the future of brain health.”
“We are very pleased with this initial step of GAP in Las Vegas and the beginning of the planned long-term relationship with UNLV.” said Jeffrey Cummings, Director of the Chambers-Grundy Center for Transformative Neuroscience in the department of brain health, Kirk Kerkorian school of medicine, UNLV.
This collaboration comes less than one year after GAP and the University of Nevada, Las Vegas (UNLV), announced a memorandum of understanding to bring next generation research to Las Vegas driven by a shared commitment to design and conduct fast and effective CNS clinical trials.
To learn when Bio-Hermes-002 is open at CNS and accepting new participants, visit clinicaltrials.gov.
About the Global Alzheimer’s Platform Foundation (GAP):
The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting inclusive clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up recruitment and retention activities and recognizing the citizen scientists who make research possible.
About Clinical Neurology Specialists (CNS)At Clinical Neurology Specialists, our team of Board Certified Neurologists and advanced practice providers treat Las Vegas and Henderson patients affected by wide variety of neurological disorders, including Alzheimer’s. CNS uses the latest EDX technologies within its AANEM accredited facilities to help diagnose patients with neurological disorders. Visit CNS website to learn more about neurology services and neurodiagnostic testing offered to Nevada residents.
